Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations

被引:101
作者
Hackel, M. [1 ]
Lascols, C. [1 ]
Bouchillon, S. [1 ]
Hilton, B. [2 ]
Morgenstern, D. [2 ]
Purdy, J. [2 ]
机构
[1] Int Hlth Management Associates, Schaumburg, IL 60173 USA
[2] Pfizer Inc, Collegeville, PA USA
关键词
Streptococcus pneumoniae; Serotype; Prevenar; Invasive pneumococcal disease; Pneumococcal conjugate vaccine; Antibiotic resistance; PNEUMOCOCCAL CONJUGATE VACCINE; COMMUNITY-ACQUIRED PNEUMONIA; ANTIMICROBIAL RESISTANCE; OLDER-ADULTS; DISEASE; EPIDEMIOLOGY; BURDEN; SUSCEPTIBILITY; CARRIAGE; EFFICACY;
D O I
10.1016/j.vaccine.2013.07.054
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Streptococcus pneumoniae remains a leading cause of disease in children and adults. Serotypes differ in invasiveness, virulence, and antibiotic resistance; therefore, serotype surveillance is necessary to monitor the burden of pneumococcal disease, especially in the setting of pneumococcal vaccination programs. The Tigecycline Evaluation Surveillance Trial, (TEST), is an on-going global antibiotic susceptibility surveillance program. Serotypes and antibiotic susceptibilities of 2173 invasive S. pneumoniae in this existing database during 2004-2008 were evaluated. Worldwide, serotypes 19A (28%), 19F (10%) and 14 (9%) were the most common in children under 5 years. In adults over 16 years, 19A (13%), 3, 6A and 7F (all 7%) were most common. Serotypes 19A, 6A, 19F, 6B, 15A, 9V, and 14 exhibited significantly higher levels of erythromycin resistance (P<0.05), while 19A, 19F, 35B, 6A, 6B, 23A, 9V, 15A, and 14 demonstrated higher rates of penicillin resistance (P<0.05). This analysis of an existing pathogen database provides a snapshot of global serotype data and describes the consequential issue of antibiotic resistance in specific serotypes, many of which are increasingly common causes of invasive pneumococcal disease. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4881 / 4887
页数:7
相关论文
共 42 条
[1]  
[Anonymous], 2011, Performance standards for antimicrobial disk susceptibility tests
[2]  
approved standard M2-A11, V11th
[3]  
[Anonymous], 2011, EPIDEMIOLOGY PREVENT
[4]  
Atkinson W, 2006, EPIDEMIOLOGY PREVENT
[5]  
AUSTRIAN R, 1976, MT SINAI J MED, V43, P699
[6]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[7]  
CfDCaP, 2019, ACT BACT COR SURV RE
[8]   Antibiotic resistance in invasive Streptococcus pneumoniae isolates identified in Scotland between 1999 and 2007 [J].
Cooke, Benjamin ;
Smith, Andrew ;
Diggle, Mathew ;
Lamb, Karen ;
Robertson, Christopher ;
Inverarity, Donald ;
Jefferies, Johanna ;
Edwards, Giles ;
Mitchell, Timothy ;
Clarke, Stuart ;
McMenamin, Jim .
JOURNAL OF MEDICAL MICROBIOLOGY, 2010, 59 (10) :1212-1218
[9]   Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine [J].
Dagan, R ;
Melamed, R ;
Muallem, M ;
Piglansky, L ;
Greenberg, D ;
Abramson, O ;
Mendelman, PM ;
Bohidar, N ;
Yagupsky, P .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (06) :1271-1278
[10]   Intrinsic Epidemicity of Streptococcus pneumoniae Depends on Strain Serotype and Antibiotic Susceptibility Pattern [J].
de Celles, Matthieu Domenech ;
Opatowski, Lulla ;
Salomon, Jerome ;
Varon, Emmanuelle ;
Carbon, Claude ;
Boelle, Pierre-Yves ;
Guillemot, Didier .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (11) :5255-5261